Ruffer LLP Buys New Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Ruffer LLP has acquired 45,097 shares of Gilead Sciences, valued at approximately $5 million, marking a significant investment in the biopharmaceutical company during the second quarter.
• Gilead Sciences announced a quarterly dividend of $0.79, set to be paid on September 29th, representing an annualized dividend of $3.16 and a yield of 2.8%.
• The company's latest earnings report showed a profit of $2.01 per share, surpassing analyst expectations, with revenues of $7.08 billion, a year-over-year increase of 1.4%.

Ruffer LLP bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 45,097 shares of the biopharmaceutical company's stock, valued at approximately $5,000,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after purchasing an additional 1,520,809 shares in the last quarter. Nuveen LLC bought a new stake in Gilead Sciences during the 1st quarter worth approximately $620,415,000. Finally, National Pension Service increased its holdings in Gilead Sciences by 6.9% during the 1st quarter. National Pension Service now owns 3,473,373 shares of the biopharmaceutical company's stock worth $389,191,000 after purchasing an additional 223,171 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 0.6%

Shares of GILD stock opened at $113.67 on Thursday. The business's fifty day moving average is $114.29 and its 200 day moving average is $110.01. Gilead Sciences, Inc. has a 52-week low of $81.83 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market capitalization of $141.04 billion, a PE ratio of 22.64, a price-to-earnings-growth ratio of 0.78 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the business posted $2.01 earnings per share. The company's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company's stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,390,030 over the last ninety days. 0.27% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Finally, Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.